Exercise of options and PDMR dealing

MXCT 10.31.2024

Full Press ReleaseSEC FilingsOur MXCT Tweets

About Gravity Analytica

Recent News

  • 01.22.2025 - Holding(s) in Company

Recent Filings

    RNS Number : 3072K
    MaxCyte, Inc.
    31 October 2024

    MaxCyte, Inc.

    ("MaxCyte" or the "Company")

    Exercise of options and PDMR dealing

    ROCKVILLE, MD,October 31, 2024:MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that on28 October 2024, as per a filing lodged with theU.S. Securities and Exchange Commission,John Johnston, aNon-Executive Director of the Company, exercised options over 3,000 shares of common stock of$0.01of the Company ("Common Stock") ("Exercise") in aggregate. The 3,000 new shares of Common Stock were issued pursuant to the Company's existing its block admission facility and were sold byJohn Johnstonat a price range between$3.700and$3.740per Common Stock ("Sale"). The sold shares represent approximately 0.9% ofJohn Johnston'stotal equity and option holdings in the Company's stock capital, respectively.

    Following the Exercise and Sale,John Johnstonholds 120,583 shares of Common Stock representing 0.1% of the issued stock capital of the Company. Following the Exercise,John Johnstonholds a further 180,918 options over Common Stock and 21,367 restricted stock units.

    The sales and option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted byJohn Johnstonon19 December 2023relating solely to the sale of shares acquired from exercise of options that expire on14 July 2027.

    MaxCyte Contacts:

    US IR Adviser

    Gilmartin Group

    David Deuchler, CFA

    +1 415-937-5400

    ir@maxcyte.com

    Nominated Adviser and Joint Corporate Broker

    Panmure Liberum

    Emma Earl/Freddy Crossley

    Corporate Broking

    Rupert Dearden

    +44 (0)20 7886 2500

    UKIR Adviser

    ICRHealthcare

    Mary-Jane Elliott

    Chris Welsh

    +44 (0)203 709 5700

    maxcyte@icrhealthcare.com

    AboutMaxCyte

    AtMaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERTTM platform, which is based on our Flow Electroporation®technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATxTM, STxTM, GTxTM and VLx TM; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more atmaxcyte.comand follow us onXandLinkedIn.

    NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

    1

    Details of the person discharging managerial responsibilities / person closely associated

    a)

    Name

    John Johnston

    2

    Reason for the notification

    a)

    Position/status

    Non-Executive Director

    b)

    Initial notification /Amendment

    Initial notification

    3

    Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

    a)

    Name

    MaxCyte, Inc.

    b)

    LEI

    54930053YHXULRFCU991

    4

    Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

    a)

    Description of the financial instrument, type of instrument

    Common Stock of$0.01each

    Identification code

    US57777K1060

    b)

    Nature of the transaction

    Exercise of Options overcommon stock

    c)

    Price(s) and volume(s)

    Exercise Price(s)

    Volume(s)

    $2.926

    3,000

    d)

    Aggregated information

    - Aggregated volume

    3,000

    - Price

    $2.926

    e)

    Date of the transaction

    28 October 2024

    f)

    Place of the transaction

    US Stock Exchange, Nasdaq

    1

    Details of the person discharging managerial responsibilities / person closely associated

    a)

    Name

    John Johnston

    2

    Reason for the notification

    a)

    Position/status

    Non-Executive Director

    b)

    Initial notification /Amendment

    Initial notification

    3

    Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

    a)

    Name

    MaxCyte, Inc.

    b)

    LEI

    54930053YHXULRFCU991

    4

    Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

    a)

    Description of the financial instrument, type of instrument

    Common Stock of$0.01each

    Identification code

    US57777K1060

    b)

    Nature of the transaction

    Sale ofcommon stock

    c)

    Price(s) and volume(s)

    Exercise Price(s)

    Volume(s)

    $3.7000

    200

    $3.7100

    383

    $3.7150

    400

    $3.7200

    450

    $3.7210

    200

    $3.7250

    300

    $3.7300

    100

    $3.7310

    200

    $3.7350

    700

    $3.7400

    67

    d)

    Aggregated information

    - Aggregated volume

    3,000

    - Price

    $3.7223

    e)

    Date of the transaction

    28 October 2024

    f)

    Place of the transaction

    US Stock Exchange, Nasdaq

    This information is provided by RNS, the news service of theLondon Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in theUnited Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contactrns@lseg.comor visitwww.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and theLondon Stock Exchangeuse the personal data you provide us, please see ourPrivacy Policy.
    END
    DSHMMBRTMTAJBPI
    Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com